Sihuan Pharmaceutical Holdings Group Ltd. announced that the National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Bireociclib tablets' new indication. The application is for the use of Bireociclib in combination with an aromatase inhibitor for the first-line treatment of HR+/HER2- advanced breast cancer. This acceptance marks a significant step in the regulatory review process for Sihuan Pharmaceutical, as the company continues to advance its innovative pharmaceutical offerings. This announcement highlights Sihuan Pharmaceutical's commitment to addressing unmet clinical needs and enhancing patient well-being.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。